

LAWSON & WEITZEN, LLP

Attorneys at Law
88 Black Falcon Avenue, Suite 345
Boston, MA 02111
Telephone (617) 439-4990
Telecopier (617) 439-3987

RECEIVED
CENTRAL FAX CENTER

FEB 18 2005

FACSIMILE TRANSMITTAL SHEET

DATE: February 18, 2005
TO: U.S. Patent and Trademark Office
FAX#: (703) 872-9306
FROM: Sonia K. Guterman, Esq., Registration Number 44,729
RE: Revocation by Assignee and New Power of Attorney

Applicants: Kinrade et al.
Serial No.: 09/771,956
Filed: January 29, 2001
For: CHIMERIC NEUROPEPTIDE Y RECEPTORS

TOTAL NUMBER OF PAGES INCLUDING COVER PAGE: 4

COMMENTS OR INSTRUCTIONS:

Attached please find a Revocation by Assignee and New Power of Attorney regarding the above U.S. Patent Application. Please do not hesitate to contact me if you have any questions.

Sonia K. Guterman
Reg. No. 44,729

This transmittal is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this transmittal is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via U.S. Postal Service. Thank you.

Facsimile: 703-872-9306
Date of Facsimile: Feb 18, 2005

Attorney Docket No.: 37737-007 (new)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kinrade et al.
Serial No.: 09/771,956
Filed: January 29, 2001
For: CHIMERIC NEUROPEPTIDE Y RECEPTORS

RECEIVED
CENTRAL FAX CENTER

FEB 18 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

Sir:

The undersigned, NEUROGEN CORPORATION, the Assignee of the entire right, title, and interest in the above-identified patent application, Serial No. 09/771,956, filed January 29, 2001, which is assigned by an assignment recorded on March 22, 2001 at Reel/Frame 011614/0298, hereby revokes any and all former powers of attorney with respect to that application heretofore granted, and appoints the below listed attorney with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith:

Attorney:

Registration No.:

Sonia K. Guterman

44,729

of Lawson & Weitzen, LLP, 88 Black Falcon Avenue, Suite 345, Boston, Massachusetts, 02210-2414, Customer No. 48425, as Applicant's attorney with full power of substitution and revocation to take any and all action necessary with regard to the above-identified application.


BEST AVAILABLE COPY

Attorney Docket No.: 37737-007 (new)

Please address all telephone calls to: Sonia K. Guterman, at telephone number 617-439-4990. Please forward all correspondence to:

Sonia K. Guterman, Esq.
Lawson & Weitzen, LLP
88 Black Falcon Avenue, Suite 345
Boston, Massachusetts
02210-2414

Respectfully submitted,
NEUROGEN CORPORATION


Name: Seth Fidel
Title: Assistant Secretary to the Corporation

Date: 16 February, 2005.

PLEASE ASSIGN PTO CUSTOMER NUMBER 48425 TO THIS APPLICATION

BEST AVAILABLE COPY

FEB-18-2005 09:38
02/17/2005 10:25

LAWSON AND WEITZEN LLP
NEUROGEN → 16174393987

617 439 3987 P.04/04
NO.183 0010

Attorney Docket No.: 37737-007 (new)


Applicants: Kinrade et al.
Serial No.: 09/771,956
Filed: January 29, 2001
For: CHIMERIC NEUROPEPTIDE Y RECEPTORS

Certification Under 37 C.F.R. §3.73(b)

NEUROGEN CORPORATION certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of assignments of the patent application identified above, which was recorded in the United States Patent and Trademark Office at Reel 011614 and Frame 0298.

The undersigned (whose title is supplied below) is authorized to act on behalf of the Assignee.

Respectfully submitted,
NEUROGEN CORPORATION


Name: Seth Fidel
Title: Assistant Secretary to the Corporation

Date: 16 February, 2005.

BEST AVAILABLE COPY